Your browser doesn't support javascript.
loading
Suspected clonal hematopoiesis as a natural functional assay of TP53 germline variant pathogenicity.
Fortuno, Cristina; McGoldrick, Kelly; Pesaran, Tina; Dolinsky, Jill; Hoang, Lily; Weitzel, Jeffrey N; Beshay, Victoria; San Leong, Huei; James, Paul A; Spurdle, Amanda B.
Afiliação
  • Fortuno C; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • McGoldrick K; Ambry Genetics, Aliso Viejo, CA.
  • Pesaran T; Ambry Genetics, Aliso Viejo, CA.
  • Dolinsky J; Ambry Genetics, Aliso Viejo, CA.
  • Hoang L; Ambry Genetics, Aliso Viejo, CA.
  • Weitzel JN; Latin American School of Oncology, Los Angeles, CA.
  • Beshay V; Molecular Pathology Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • San Leong H; Molecular Pathology Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • James PA; Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, and Royal Melbourne Hospital, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia. Electronic address:
  • Spurdle AB; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. Electronic address: Amanda.spurdle@qimrberghofer.edu.au.
Genet Med ; 24(3): 673-680, 2022 03.
Article em En | MEDLINE | ID: mdl-34906512
ABSTRACT

PURPOSE:

Some variants identified by multigene panel testing of DNA from blood present with low variant allele fraction (VAF), often a manifestation of clonal hematopoiesis. Research has shown that the proportion of variants with low VAF is especially high in TP53, the Li-Fraumeni syndrome gene. Based on the hypothesis that variants with low VAF are positively selected as drivers of clonal hematopoiesis, we investigated the use of VAF as a predictor of TP53 germline variant pathogenicity.

METHODS:

We used data from 260,681 TP53 variants identified at 2 laboratories to compare the distribution of pathogenic and benign variants at different VAF intervals.

RESULTS:

Likelihood ratios toward pathogenicity associated with a VAF < 26% equated to the American College of Medical Genetics/Association of Molecular Pathology strong strength level and were applicable for 1 in 5 variants of unknown significance.

CONCLUSION:

In conclusion, detection of variants with low VAF in blood can be considered an in vivo functional assay to aid assessment of TP53 variant pathogenicity.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Predisposição Genética para Doença / Hematopoiese Clonal Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Predisposição Genética para Doença / Hematopoiese Clonal Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article